Proactive Multifactorial Intervention Strategy Reduces the Risk of Cardiovascular Disease Estimated with Region-Specific Risk Assessment Models in Pacific Asian Patients Participating in the CRUCIAL Trial.
10.3346/jkms.2013.28.12.1741
- Author:
Eun Joo CHO
1
;
Jae Hyung KIM
;
Santosh SUTRADHAR
;
Carla YUNIS
;
Mogens WESTERGAARD
Author Information
1. Department of Cardiology, St Paul's Hospital, The Catholic University of Korea, Seoul, Korea. jhkim480kr@naver.com
- Publication Type:Original Article ; Clinical Trial ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Cardiovascular Diseases;
Risk Factors;
Hypertension;
Clinical Trial;
Antihypertensive Agents;
Anticholesteremic Agents
- MeSH:
Adult;
Age Factors;
Aged;
Asian Continental Ancestry Group/*statistics & numerical data;
Blood Pressure;
Cardiovascular Diseases/*etiology;
Cholesterol, LDL/blood;
Female;
Follow-Up Studies;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use;
Hypertension/diagnosis/drug therapy;
Male;
Middle Aged;
Risk Assessment;
Sex Factors;
Treatment Outcome;
Triglycerides/blood
- From:Journal of Korean Medical Science
2013;28(12):1741-1748
- CountryRepublic of Korea
- Language:English
-
Abstract:
Despite race, ethnic, and regional differences in cardiovascular disease risk, many worldwide hypertension management guidelines recommend the use of the Framingham coronary heart disease (CHD) risk equation to guide treatment decisions. This subanalysis of the recently published CRUCIAL trial compared the treatment-related reductions in calculated CHD and stroke risk among Pacific Asian (PA) patients using a variety of region-specific risk assessment models. As a result, greater reductions in systolic and diastolic blood pressure, low-density lipoprotein cholesterol, and triglycerides were observed in the proactive multifactorial intervention (PMI) arm compared with the usual care arm at Week 52 for PA patients. The relative percentage change in 10-yr CHD risk between baseline and Week 52 in the PMI versus usual care arms was greatest using the NIPPON DATA80 fatal CHD model (LS [least square] mean difference -42.6%), and similar in the SCORE fatal CHD and Framingham total CHD models (LS mean difference -29.4% and -30.8%, respectively). The single-pill based PMI approach is consistently effective in reducing cardiovascular disease risk, evaluated using a variety of risk assessment models. (ClinicalTrials.gov registration number: NCT00407537)
